# Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

> **NCT00361140** · PHASE4 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 72 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Leukemia, Lymphocytic
- Myeloma
- Lymphoma

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT00361140
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361140, "Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00361140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*